BenevolentAI Submits CTA for BEN-8744, Oral PDE10 Inhibitor, as First-in-Class Treatment for Ulcerative Colitis
BEN-8744 demonstrates the potential of the Benevolent Platform™️ to discover new targets not previously associated with a particular disease The start of Phase I of the clinical trial is planned for the first half of 2023 LONDON, December 21, 2022—(BUSINESS WIRE)–BenevolentAI (Euronext Amsterdam: BAI), a leading AI-powered clinical-stage drug discovery company, announces that it has …